BSIM Therapeutics
Small Molecule Therapeutics against Transthyretin-Mediated Amyloidoses
Business Model:
Revenue: $0
Employees: 1-10
Rankings
Industries / Tags:
Detailed BSIM Therapeutics Information
Geographic Data
Address:
City: Coimbra
State: Coimbra
Zip:
Country: Portugal
Financial Info
Stage:
seed
Raised Last:
$583k
Raised Total:$3M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
BSIM’s mission is to deliver quality drug candidates with high capital efficiency against transthyretin-mediated amyloidosis, including clinical manifestations and related pathologies that represent important and unmet medical needs. Our products are directed to a group of rare, hereditary and fatal pathologies commonly addressed to as Transthyretin Amyloidoses (hATTR). We are developing drug candidates that fit within distinct target-product profiles for the treatment of a broader range of hATTR manifestations, including central nervous system symptoms (e.g. seizures, stroke-like events, progressive dementia) and oculopathy (e.g. vitreous opacities, glaucoma).
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2011 | Private Equity Round | $7.1k | 6/2012 | Grant | $930.1k | 2/2017 | Seed Round | 1 | $582.9k |
Portugal Ventures Portugal Ventures |
8/2016 | Grant | $1.1M | 6/2012 | Pre Seed Round | 2 | $297.6k |
a2b SGPS Bluepharma – Indústria Farmacêutica a2b SGPS Bluepharma – Indústria Farmacêutica |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
